IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) from its SEC filings: 2025 revenue $263.5 million (+61% vs the year before), net margin -148%, free cash flow -$336.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $263.5 million |
| Revenue growth | +61% |
| Net income | -$391.0 million |
| Net margin | -148.4% |
| Free cash flow | -$336.2 million |
| Diluted EPS | $-1.09 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +66% |
| Cash | $110.8 million |
| Share count, 1 year | +25% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.